Connecticut State Department of Public Health

COVID-19 Community Levels Update, March 31, 2023: The CDC has listed all eight Connecticut counties in the Low/Green category as part of its weekly Community Levels update. People who are at a high risk for severe illness should consider additional measures to minimize their exposure to COVID-19 and respiratory illnesses. Visit the CDC COVID-19 Community Levels Map for updates.

Please visit covidtests.gov to request four free COVID-19 self-test kits from the Federal Government. Find a location that has a supply of COVID-19 therapeutics as part of the Test to Treat initiative here. The complete DPH COVID-19 toolbox is located at ct.gov/coronavirus.

Press Releases

02/03/2023

CDC and the Connecticut Department of Public Health urge residents to stop using EzriCare Artificial Tears due to numerous infections

FOR IMMEDIATE RELEASE: Feb. 3, 2023

CONTACT:     Chris Boyle, Director of Communications

                        (860) 706-9654 – christopher.boyle@ct.gov

 

HARTFORD, Conn. — The Centers for Disease Control and Prevention is recommending that consumers and health care providers immediately stop using EzriCare Artificial Tears following its investigation of numerous infections linked to the eye drops.

 

Infections have been found in 55 patients in 12 states including Connecticut and occurred between May 2022-January 2023. Most of those affected had used artificial tears with the most commonly used brand being EzriCare, which is available over the counter. Patient outcomes included vision loss, hospitalization, and the death of one patient with a bloodstream infection.

 

“The Pseudomonas bacteria that have been found in the EzriCare product are highly resistant to antibiotics,” said Connecticut Department of Public Health Commissioner Manisha Juthani, MD. “Infections with the bacteria can develop in the eyes, blood, lungs, and urinary tract.”

 

Patients who have used EzriCare Artificial Tears and have signs or symptoms of an eye infection, such as discharge from the eye, eye pain or discomfort, redness of the eye or eyelid, feeling of something in the eye, increased sensitivity to light, or blurry vision, should seek timely medical care.

 

“The CDC also recommends that if patients were advised to use EzriCare Artificial Tears that they should stop immediately and follow up with their health care provider for an alternate product to use,” said Commissioner Juthani.

 

For more information on this outbreak, visit the CDC website

 

-30-